VIR BIOTECHNOLOGY, I

VIR
Delayed Quote. Delayed  - 05/13 04:00:00 pm
39.55USD +1.13%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2020 2021
Net sales1 76,4375
EBITDA1 -292-193
Operating profit (EBIT)1 -297-220
Operating Margin -389%-58,6%
Pre-Tax Profit (EBT)1 -299-211
Net income1 -299-274
Net margin -391%-73,0%
EPS2 -2,51-2,16
Dividend per Share2 --
Last update 02/25/202105/07/2021
1 USD in Million
2 USD
Estimates
Finances - Leverage
Fiscal Period: December 2020 2021
Net Debt1 --
Net Cash position1 737364
Leverage (Debt / EBITDA) 2,53x1,88x
Free Cash Flow1 -197-119
ROE (Net Profit / Equities) -52,4%-65,7%
Shareholders' equity1 570417
ROA (Net Profit / Asset) -41,7%-48,8%
Assets1 715561
Book Value Per Share --
Cash Flow per Share2 -1,60-0,07
Capex1 6,557,95
Capex / Sales 8,58%2,12%
Last update 02/25/202105/13/2021
1 USD in Million
2 USD
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2021e 2022e
Capitalization 5 143 M $ -
Entreprise Value (EV) 4 779 M $ 4 448 M $
Valuation 2021e 2022e
P/E ratio (Price / EPS) -18,3x -43,7x
Capitalization / Revenue 13,7x 8,45x
EV / Revenue 12,7x 7,86x
EV / EBITDA -24,7x 108x
Yield (DPS / Price) - -
Price to book (Price / BVPS) - -
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) -58,6% -10,3%
Operating Leverage (Delta EBIT / Delta Sales) 0,07x 1,15x
Net Margin (Net Profit / Revenue) -73,0% -20,5%
ROA (Net Profit / Asset) -48,8% -38,5%
ROE (Net Profit / Equities) -65,7% -51,5%
Rate of Dividend - -
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   2,12% 1,72%
Cash Flow / Sales -2,44% -0,89%
Capital Intensity (Assets / Sales) 1,50x 0,53x
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
EPS & Dividend